Key Highlights

  • Neogen closed around $12.21 during the regular session, then jumped to about $13.00 in after-hours trading on its fiscal first-quarter results.
  • Revenue came in at $222.8 million, comfortably ahead of the roughly $208.3 million analysts had expected.
  • Adjusted Earnings came to $0.08 a share, with the chief executive citing encouraging progress on changes under way across the business.
  • Health care was the only S&P 500 sector to decline during the regular session, part of the backdrop for Neogen's daytime weakness.

Neogen (NASDAQ:NEOG), which sells testing kits and services that help food producers and animal-health customers detect contaminants, pathogens and residues, had a whiplash day on Tuesday, October 6. During the regular session the stock fell and closed around $12.21, as health care struggled across the market.

The picture changed after the close, when the company released results for its fiscal first quarter. Shares jumped in after-hours trading to about $13.00, with one source putting the price near $13.02. One other data provider showed a different after-hours direction, so the size of the late move should be treated with some caution until regular trading resumes. The swing made Neogen one of the most-talked-about names connected to the S&P MidCap 400.

What the Numbers Showed

Neogen reported Revenue of $222.8 million for the quarter, comfortably ahead of the roughly $208.3 million analysts had expected. Adjusted earnings came to $0.08 a share.

Chief executive Mike Nassif described the quarter as showing encouraging progress on changes under way across the business. Investors have been watching for evidence of how those changes are showing up in sales and margins. A clear revenue beat is the kind of data point that can shift sentiment quickly, which may help explain the after-hours response.

A Tough Day for Health Care

The regular-session decline came against an awkward backdrop for the sector. Health care was the only S&P 500 sector to fall on Tuesday, with life-science tools and diagnostics names such as Danaher (NYSE:DHR), Thermo Fisher (NYSE:TMO), Bruker (NASDAQ:BRKR) and GRAIL (NASDAQ:GRAL) under pressure. Vaccine makers Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) slid after the World Health Organization lowered its plague risk assessment to low. Only 48 of 428 health-care stocks in the Russell 2000 advanced.

The broad market, by contrast, was buoyant. The S&P 500 gained 44.98 points to a record close of 7,818.93, the Nasdaq Composite set a record just under 27,600, and the Dow Jones Industrial Average rose 253.38 points to 51,521.28. Treasury yields eased, with the 10-year near 5.28, and the VIX Volatility gauge settled around 15. Small caps lagged, however, with the Russell 2000 slipping to about 2,830.

Neogen's food-safety Business tends to be less tied to economic cycles than many industrial companies, since testing requirements remain in place regardless of Demand swings. But the stock still trades with investor appetite for health-care and diagnostics names, which was weak during the day.

Other After-Hours Reporters

Neogen was one of several companies to report after Tuesday's close. Constellation Brands (NYSE:STZ) posted quarterly results with a choppy after-hours reaction, as sources differed on the direction of its shares, and Penguin Solutions (NASDAQ:PENG) rose after its own report.

Wednesday's Open Will Test the Gain

The key question is whether Neogen's after-hours gain holds once full trading resumes and more investors have digested the results. Analysts are likely to update their estimates and price targets after the earnings call, and any detail on full-year guidance, margins and the changes under way across the business will be closely parsed.